Date: 2013-06-07
Type of information: Financing round
Company: Diagnoplex (Switzerland)
Investors: Debiopharm (Switzerland)
Neomed (Switzerland)
Initiative Capital Romandie (Switzerland)
Amount: 1.3 million Swiss francs (€1.03 million)
Funding type: financing round
Planned used: The funds will be used to help Diagnoplex obtain CE marking for Colox, a non-invasive blood-based test for the early detection of colon cancer. The company also wishes to prepare a comparative clinical trial with the screening test that should allow for patient reimbursement.
Others: * On June 7, 2013, Diagnoplex SA, a developer of molecular diagnostics for colon cancer has secured 1.3 million Swiss francs (€1.03 million) from a financing round led by Debiopharm. Other investors include Neomed and Initiative Capital Romandie.
Diagnoplex’s lead product, Colox®, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox® has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox® leverages the information from nucleic acids carried by peripheral blood mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the so-called “host response”, and are involved at the earliest stages of tumor formation.
Therapeutic area: Diagnostic - Cancer - Oncology
